Further studies are needed to understand the regulatory mechanisms of ALDH9A1 and its potential as a prognostic biomarker or therapeutic target in ovarian cancer, particularly in the context of residual disease and chemoresistance. Here, ALDH9A1 is linked to ovarian carcinoma.